These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24745679)

  • 1. Eosinophilia in mast cell disease.
    Kovalszki A; Weller PF
    Immunol Allergy Clin North Am; 2014 May; 34(2):357-64. PubMed ID: 24745679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
    Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
    Helbig G; Kyrcz-Krzemień S
    Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
    [No Abstract]   [Full Text] [Related]  

  • 5. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
    Gilliland G; Cools J; Stover EH; Wlodarska I; Marynen P
    Hematol J; 2004; 5 Suppl 3():S133-7. PubMed ID: 15190295
    [No Abstract]   [Full Text] [Related]  

  • 6. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.
    Klion AD; Noel P; Akin C; Law MA; Gilliland DG; Cools J; Metcalfe DD; Nutman TB
    Blood; 2003 Jun; 101(12):4660-6. PubMed ID: 12676775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
    Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
    Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FIP1L1-PDGFRα-positive hypereosinophilic syndrome in childhood: a case report and review of literature.
    Farruggia P; Giugliano E; Russo D; Trizzino A; Lorenzatti R; Santoro A; D'Angelo P
    J Pediatr Hematol Oncol; 2014 Jan; 36(1):e28-30. PubMed ID: 23337549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
    Yamada Y; Cancelas JA; Rothenberg ME
    Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
    Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
    Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response?
    Pitini V; Arrigo C; Altavilla G; Naro C; Righi M
    Leuk Res; 2007 May; 31(5):725-6. PubMed ID: 16978696
    [No Abstract]   [Full Text] [Related]  

  • 12. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.
    Gotlib J; Akin C
    Semin Hematol; 2012 Apr; 49(2):128-37. PubMed ID: 22449623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
    Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
    Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
    Pitini V; Sturniolo G; Cavallari V; Arrigo C
    Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
    [No Abstract]   [Full Text] [Related]  

  • 15. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
    Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.
    Maric I; Robyn J; Metcalfe DD; Fay MP; Carter M; Wilson T; Fu W; Stoddard J; Scott L; Hartsell M; Kirshenbaum A; Akin C; Nutman TB; Noel P; Klion AD
    J Allergy Clin Immunol; 2007 Sep; 120(3):680-7. PubMed ID: 17628645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Identification of clonal proliferation of T cell and FIP1L1-PDGFRalpha fusion gene in hypereosinophilic syndrome associated with lymphomatoid papulosis which showed rapid and complete response to the treatment with imatinib].
    Fujimi A; Kanisawa Y; Kikuchi S; Okuda T; Sato Y; Doi T; Ohta H; Umeda I; Nobuoka A
    Nihon Naika Gakkai Zasshi; 2007 Dec; 96(12):2794-7. PubMed ID: 18203417
    [No Abstract]   [Full Text] [Related]  

  • 19. FIP1L1/PDGFR alpha-associated systemic mastocytosis.
    Yamada Y; Cancelas JA
    Int Arch Allergy Immunol; 2010; 152 Suppl 1(Suppl 1):101-5. PubMed ID: 20523072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
    Klion AD; Robyn J; Maric I; Fu W; Schmid L; Lemery S; Noel P; Law MA; Hartsell M; Talar-Williams C; Fay MP; Dunbar CE; Nutman TB
    Blood; 2007 Nov; 110(10):3552-6. PubMed ID: 17709602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.